{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:59:26Z","timestamp":1781243966752,"version":"3.54.1"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:p>Proteolysis Targeting Chimera (PROTAC) is an innovative drug discovery strategy that utilizes bifunctional small molecules to bring a target protein (POI) into proximity with an E3 ubiquitin ligase, thereby inducing ubiquitination of the pathogenic protein and its subsequent degradation by the proteasome. PROTACs exhibit a novel mechanism of action, catalytic efficiency, high selectivity, and broad applicability. They have achieved significant breakthroughs, particularly in oncology, with several molecules currently in phase II\/III clinical trials. The application of PROTAC technology in antiviral drug development remains in the early exploratory stage. However, since most antiviral targets are viral proteins, targeted clearance of these pathogenic proteins is unlikely to cause adverse side effects. PROTACs hold particular promise in chronic viral infections such as hepatitis B virus (HBV), where degradation of proteins like HBx and HBcAg, in combination with existing therapies, may help overcome the challenges of achieving a cure. This article summarizes recent advances in PROTAC-based anti-hepatitis research and critically discusses both the opportunities and challenges in developing PROTACs as next-generation antiviral therapeutics. It also highlights the role and characteristics of fluorine in the design of drugs for treating hepatitis.<\/jats:p>","DOI":"10.3389\/fchem.2026.1810498","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:44:59Z","timestamp":1781243099000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Research progress of proteolysis-targeting chimeras in viral hepatitis drug discovery"],"prefix":"10.3389","volume":"14","author":[{"given":"Xiaofei","family":"Hao","sequence":"first","affiliation":[{"name":"School of Chemical Engineering Zhengzhou University","place":["Zhengzhou, China"]},{"name":"High and New Technology Research Center, Henan Academy of Science","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Chemical Engineering Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Chemical Engineering Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyang","family":"Lin","sequence":"additional","affiliation":[{"name":"High and New Technology Research Center, Henan Academy of Science","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[{"name":"High and New Technology Research Center, Henan Academy of Science","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wubin","family":"Zhi","sequence":"additional","affiliation":[{"name":"Institute of Chemistry of Henan Academy of Sciences","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiankai","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Chemistry of Henan Academy of Sciences","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Qi","sequence":"additional","affiliation":[{"name":"Institute of Chemistry of Henan Academy of Sciences","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Chemical Engineering Zhengzhou University","place":["Zhengzhou, China"]},{"name":"Institute of Chemistry of Henan Academy of Sciences","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the role of linker design in proteolysis targeting chimeras","volume":"64","author":"Bemis","year":"2021","journal-title":"J. Med. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2017","journal-title":"Cell. Chem. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/s2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. The lancet","volume":"1","author":"Buti","year":"2016","journal-title":"Gastroenterology and Hepatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"835344","DOI":"10.3389\/fmicb.2022.835344","article-title":"Dual-role ubiquitination regulation shuttling the entire life cycle of the Flaviviridae","volume":"13","author":"Cai","year":"2022","journal-title":"Front. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"12273","DOI":"10.1021\/acs.jmedchem.1c00901","article-title":"Folate-guided protein degradation by immunomodulatory imide drug-based molecular glues and proteolysis targeting chimeras","volume":"64","author":"Chen","year":"2021","journal-title":"J. Med. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"12852","DOI":"10.1039\/d1cc05715d","article-title":"Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia","volume":"57","author":"Cheng","year":"2021","journal-title":"Chem. Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1021\/acs.jmedchem.7b00635","article-title":"Identification and characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1","volume":"61","author":"Crew","year":"2017","journal-title":"J. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"De Wispelaere","year":"2019","journal-title":"Nat. Commun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.tibs.2025.07.009","article-title":"E3 ubiquitin ligases in signaling, disease, and therapeutics","volume":"50","author":"Ebadi","year":"2025","journal-title":"Trends Biochem. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"11734","DOI":"10.1021\/jacs.9b13907","article-title":"Efficient targeted degradation via reversible and irreversible covalent PROTACs","volume":"142","author":"Gabizon","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"101062","DOI":"10.1016\/j.xcrp.2022.101062","article-title":"Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy","volume":"3","author":"Han","year":"2022","journal-title":"Cell. Rep. Phys. Sci."},{"key":"B15","volume-title":"The Preparation of Protacs Targeting Hepatitis B Virus and Usage Thereof","author":"Hao","year":"2025"},{"key":"B16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","article-title":"PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e18484","DOI":"10.1111\/jcmm.18484","article-title":"SIAH2 suppresses c\u2010JUN pathway by promoting the polyubiquitination and degradation of HBx in hepatocellular carcinoma","volume":"28","author":"Hu","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","article-title":"A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader","volume":"25","author":"Huang","year":"2017","journal-title":"Cell. Chem. Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4288","DOI":"10.1007\/s12035-018-1359-3","article-title":"Neuroimmunomodulation in major depressive disorder: focus on caspase 1, inducible nitric oxide synthase, and interferon-gamma","volume":"56","author":"Inserra","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1099\/jgv.0.001337","article-title":"HBx natural variants containing Ser-101 instead of Pro-101 evade ubiquitin-dependent proteasomal degradation by activating proteasomal activator 28 gamma expression","volume":"100","author":"Jeong","year":"2019","journal-title":"J. General Virology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"110199","DOI":"10.1016\/j.virol.2024.110199","article-title":"Ubiquitin: a double-edged sword in hepatitis B virus-induced hepatocellular carcinoma","volume":"599","author":"Kar","year":"2024","journal-title":"Virology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/13543776.2022.1999415","article-title":"Ligands for cereblon: 2017\u20132021 patent overview","volume":"32","author":"Kazantsev","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"B23","first-page":"439","article-title":"Emerging therapies toward a functional cure for hepatitis B virus infection","volume":"14","author":"Kim","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","article-title":"The ubiquitin code","volume":"81","author":"Komander","year":"2012","journal-title":"Annu. Rev. Biochem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000360947","article-title":"Genotypes and genetic variability of hepatitis B virus","volume":"57","author":"Kramvis","year":"2014","journal-title":"Intervirology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"B27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.3390\/molecules27196515","article-title":"Discovery of E3 ligase ligands for target protein degradation","volume":"27","author":"Lee","year":"2022","journal-title":"Molecules"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/d2cs00193d","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"129680","DOI":"10.1016\/j.bmcl.2024.129680","article-title":"\u201cPROTAC\u201d modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro","volume":"102","author":"Li","year":"2024","journal-title":"Bioorg. and Med. Chem. Lett."},{"key":"B32","doi-asserted-by":"publisher","first-page":"100092","DOI":"10.1016\/j.cellin.2023.100092","article-title":"Antiviral PROTACs: opportunity borne with challenge","volume":"2","author":"Liang","year":"2023","journal-title":"Cell. Insight"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/hep.30231","article-title":"Hepatitis B virus core variants, liver fibrosis, and hepatocellular carcinoma","volume":"69","author":"Ligat","year":"2018","journal-title":"Hepatology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jvh.12613","article-title":"No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg\u2212 patients with chronic hepatitis B after 8 years of treatment","volume":"24","author":"Liu","year":"2016","journal-title":"J. Viral Hepat."},{"key":"B35","doi-asserted-by":"publisher","first-page":"eaay5154","DOI":"10.1126\/sciadv.aay5154","article-title":"Light-induced control of protein destruction by opto-PROTAC","volume":"6","author":"Liu","year":"2020","journal-title":"Sci. Adv."},{"key":"B36","volume-title":"A Bifunctional Derivative Containing Dihydropyrimidine and Usage Thereof","author":"Liu","year":"2021"},{"key":"B37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta\u2010analysis","volume":"63","author":"Lok","year":"2015","journal-title":"Hepatology"},{"key":"B38","article-title":"Study on the Deuterated Drug and Structural Optimization Based on Targets and Mechanisms of Action of HBV Capsid Protein Inhibitor GLS4","author":"Ma","year":"2021"},{"key":"B39","doi-asserted-by":"publisher","first-page":"12558","DOI":"10.3748\/wjg.v21.i44.12558","article-title":"Hepatitis B virus therapy: what\u2019s the future holding for Us?","volume":"21","author":"Manzoor","year":"2015","journal-title":"World J. Gastroenterology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bbrc.2014.10.006","article-title":"Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus","volume":"453","author":"Montrose","year":"2014","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02221-18","article-title":"Validating enterovirus D68-2A pro as an antiviral drug target and the discovery of telaprevir as a potent D68-2A pro inhibitor","volume":"93","author":"Musharrafieh","year":"2019","journal-title":"J. Virology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1021\/acs.jnatprod.6b00878","article-title":"Metabolites from the plant endophytic fungus aspergillus sp. CPCC 400735 and their Anti-HIV activities","volume":"80","author":"Pang","year":"2017","journal-title":"J. Nat. Prod."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1111\/liv.13059","article-title":"Entecavir plus tenofovir combination therapy in patients with multidrug\u2010resistant chronic hepatitis B: results of a multicentre, prospective study","volume":"36","author":"Park","year":"2016","journal-title":"Liver Int."},{"key":"B44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting chimeras (PROTACs) \u2014 past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev.biochem.70.1.503","article-title":"Mechanisms underlying ubiquitination","volume":"70","author":"Pickart","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"105107","DOI":"10.1016\/j.antiviral.2021.105107","article-title":"E3 ubiquitin ligase TRIM21 restricts hepatitis B virus replication by targeting HBx for proteasomal degradation","volume":"192","author":"Song","year":"2021","journal-title":"Antivir. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1039\/d2cs00148a","article-title":"E3 ligase ligand chemistries: from building blocks to protein degraders","volume":"51","author":"Sosi\u010d","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"B49","volume-title":"Compound for Degrading Deoxyribonlcleic Acid (DNA) Polymerase, and Use Thereof","author":"Su","year":"2022"},{"key":"B50","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-Induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell. Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2015","journal-title":"Hepatology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1021\/acschembio.8b01094","article-title":"PROTAC-mediated degradation of Bruton\u2019s tyrosine kinase is inhibited by covalent binding","volume":"14","author":"Tinworth","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/s0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Tr\u00e9po","year":"2014","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1021\/acsmedchemlett.2c00446","article-title":"Discovery of coumarin-based MEK1\/2 PROTAC effective in human cancer cells","volume":"14","author":"Wang","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"B56","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1053\/j.gastro.2018.10.048","article-title":"What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats","volume":"156","author":"Ward","year":"2018","journal-title":"Gastroenterology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"571166","DOI":"10.3389\/fimmu.2020.571166","article-title":"Reversal of immunity after clearance of chronic HCV infection\u2014all reset?","volume":"11","author":"Wedemeyer","year":"2020","journal-title":"Front. Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.apsb.2021.12.017","article-title":"NAMPT-Targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion","volume":"12","author":"Wu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"B59","doi-asserted-by":"publisher","first-page":"13487","DOI":"10.1021\/acs.jmedchem.1c00900","article-title":"Discovery of ARD-2585 as an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer","volume":"64","author":"Xiang","year":"2021","journal-title":"J. Med. Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1016\/j.apsb.2022.02.009","article-title":"A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization","volume":"12","author":"Yang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"B61","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ncb3358","article-title":"The increasing complexity of the ubiquitin code","volume":"18","author":"Yau","year":"2016","journal-title":"Nat. Cell. Biol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1099\/jgv.0.000856","article-title":"Hepatitis B virus X protein activates E3 ubiquitin ligase Siah-1 to control virus propagation via a negative feedback loop","volume":"98","author":"Yeom","year":"2017","journal-title":"J. General Virology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e202114957","DOI":"10.1002\/ange.202114957","article-title":"Smart Nano\u2010PROTACs reprogram tumor microenvironment for activatable photo\u2010metabolic cancer immunotherapy","volume":"134","author":"Zhang","year":"2021","journal-title":"Angew. Chem."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1016\/j.febslet.2011.08.015","article-title":"E3 ubiquitin ligase Siah-1 facilitates poly-ubiquitylation and proteasomal degradation of the hepatitis B viral X protein","volume":"585","author":"Zhao","year":"2011","journal-title":"FEBS Lett."},{"key":"B65","doi-asserted-by":"publisher","first-page":"42374","DOI":"10.1038\/srep42374","article-title":"Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1810498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:45:01Z","timestamp":1781243101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1810498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":65,"alternative-id":["10.3389\/fchem.2026.1810498"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2026.1810498","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1810498"}}